9/23/2026, 5:00:07 AM
NORWOOD, Mass. — September 23, 2026 — Leads & Copy — MariMed Inc. announced it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission to seek stockholder approval for a proposed reverse stock split. The meeting to discuss the proposal is scheduled for October 28, 2026.
The reverse stock split is intended to provide MariMed with increased flexibility to meet the minimum share price and other requirements necessary for a potential listing of its common stock on a U.S. national securities exchange. If approved by stockholders, the reverse stock split will be implemented at the sole discretion of the Board of Directors.
Jon Levine, Chief Executive Officer of MariMed, stated that positioning the company to pursue a listing on a major U.S. exchange is a significant step in its development. A national exchange listing could broaden the investor base by enhancing visibility among institutional investors, research analysts, and broker-dealers, and improve access to capital markets. Levine added that in the evolving regulatory and capital market landscape for the cannabis industry, these measures offer greater strategic flexibility.
The company cautioned that there is no guarantee the Board will proceed with the reverse stock split, that MariMed will qualify for listing on a U.S. national exchange, or that the split will satisfy all listing requirements or result in a sustained increase in the trading price or liquidity of its common stock.
If the reverse stock split is approved, the Board will have the authority to determine whether and when to implement it, with a ratio between one for fifty and one for one-hundred. The final ratio will be decided by the Board based on market conditions and other factors, including potential U.S. national exchange listing requirements. The Board retains the discretion not to proceed if it determines it would not be in the best interests of the company and its stockholders.
No fractional shares will be issued. Stockholders entitled to a fractional share will receive a cash payment in lieu thereof. The reverse stock split would reduce the number of outstanding shares of MariMed common stock by the applicable split ratio. This action, by itself, is not expected to change a stockholder’s proportional ownership or voting power, except for adjustments related to fractional shares.
Stockholders of record as of the close of business on September 4, 2026, are eligible to vote on the reverse stock split proposal at the Special Meeting. The definitive proxy statement, filed with the SEC on September 22, 2026, contains comprehensive information regarding the proposal, including its rationale and associated risks, and is available on the SEC’s website and MariMed’s Investor Relations website.
MariMed Inc. is a multi-state cannabis operator that develops and manages cultivation, production, and retail facilities. Its portfolio includes brands such as Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™.
Source: MariMed Inc.
